| 1.24 0.055 (4.64%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.58 | 1-year : | 1.75 |
| Resists | First : | 1.35 | Second : | 1.5 |
| Pivot price | 1.23  |
|||
| Supports | First : | 1.12 | Second : | 0.93 |
| MAs | MA(5) : | 1.18 |
MA(20) : | 1.24 |
| MA(100) : | 1.26 |
MA(250) : | 1.35 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 22.4 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 2.42 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EVGN ] has closed below upper band by 46.5%. Bollinger Bands are 40.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.29 | 1.29 - 1.29 |
| Low: | 1.2 - 1.2 | 1.2 - 1.21 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Thu, 06 Nov 2025
Evogene (NASDAQ: EVGN) sets November 20 results release; call 9:00 AM ET via Zoom - Stock Titan
Thu, 06 Nov 2025
Evogene Schedules Third Quarter 2025 Financial Results Release - PR Newswire
Tue, 30 Sep 2025
Evogene Ltd. Releases Financial Results for First Half of 2025 - TipRanks
Wed, 20 Aug 2025
Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... - Yahoo Finance
Tue, 10 Jun 2025
Evogene's New AI Model Achieves 90% Precision in Drug Discovery, Crushing Traditional 29% Success Rate - Stock Titan
Tue, 10 Jun 2025
Evogene’s Financial Turnaround: A Deep Dive - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 98 (K) |
| Shares Short P.Month | 93 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | -151 % |
| Operating Margin | -347.4 % |
| Return on Assets (ttm) | -32.4 % |
| Return on Equity (ttm) | -89.4 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 0.65 |
| Sales Per Share | 1.08 |
| EBITDA (p.s.) | -2.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | -3.03 |
| Price to Sales | 1.14 |
| Price to Cash Flow | -0.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|